
Hugues de Lavallade

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9599036/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib. Blood Cancer Journal, 2022, 12, 73.	6.2	7
2	Evidence of robust memory Tâ€cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2). British Journal of Haematology, 2021, 193, 692-696.	2.5	13
3	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. Leukemia, 2021, 35, 3573-3577.	7.2	41
4	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2) induces neutralising antibody and polyfunctional Tâ€cell responses in patients with chronic myeloid leukaemia. British Journal of Haematology, 2021, 194, 999-1006.	2.5	55
5	Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional TÂcell response in allogeneic stem cell transplantation recipients. Cancer Cell, 2021, 39, 1448-1449.	16.8	29
6	Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML. Blood, 2020, 136, 51-53.	1.4	5
7	Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. Lancet Haematology,the, 2019, 6, e276-e284.	4.6	46
8	Prospective Evaluation of ABL Kinase Domain Mutational Analysis By Next-Generation-Sequencing in Newly Diagnosed CP CML Patients Undergoing First-Line Treatment with Nilotinib Alone or Nilotinib + Pegylated Interferon-α2a in a Prospective Phase III Trial. Blood, 2019, 134, 664-664.	1.4	4
9	Mechanistic Insights into the Inhibition of T Regulatory Cells By Dasatinib May Predict Immunostimulatory Effects in CML Patients. Blood, 2019, 134, 1635-1635.	1.4	1
10	The Role of Early Molecular Response in the Management of Chronic Phase CML. Current Hematologic Malignancy Reports, 2017, 12, 79-84.	2.3	15
11	Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of 533 Adult Patients Who Underwent Transplantation at King's College Hospital. Biology of Blood and Marrow Transplantation, 2015, 21, 60-66.	2.0	62
12	Impact of Finding of Low Level Kinase Domain Mutations Using Ultra Deep Next Generation Sequencing in Patients with Chronic Phase CML. Blood, 2015, 126, 347-347.	1.4	7
13	Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. Blood, 2013, 122, 227-238.	1.4	97
14	Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host. Haematologica, 2011, 96, 307-314.	3.5	113
15	Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets,. Blood, 2011, 118, 3753-3753.	1.4	Ο
16	Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy Blood, 2010, 116, 3414-3414.	1.4	6
17	Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs. Blood, 2010, 116, 2274-2274.	1.4	1
18	KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib. Blood, 2010, 116, 888-888.	1.4	0

Hugues de Lavallade

#	Article	IF	CITATIONS
19	2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection. Blood, 2010, 116, 677-677.	1.4	0
20	A Distinct Signature of Natural Killer Cell KIR Gene Frequencies In Secondary AML Compared with De Novo AML and Normal Controls. Blood, 2010, 116, 1697-1697.	1.4	0
21	Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients Blood, 2009, 114, 3290-3290.	1.4	10
22	BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML Blood, 2009, 114, 3248-3248.	1.4	0
23	T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors Blood, 2009, 114, 2214-2214.	1.4	0
24	Presence of the Killer Immunoglobulin-Like Gene KIR3DS1 Is Associated with Poor Progression Free and Overall Survival Following Autologous Stem Cell Transplantation in Patients with Myeloma Blood, 2009, 114, 2840-2840.	1.4	0
25	Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy Blood, 2007, 110, 1037-1037.	1.4	2
26	Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution Blood, 2007, 110, 1045-1045.	1.4	1
27	Pleural Effusions Associated with Use of Dasatinib in Chronic Myeloid Leukemia May Have an Auto-Immune Pathogenesis Blood, 2007, 110, 2945-2945.	1.4	3
28	For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance Blood, 2007, 110, 323-323.	1.4	6